10 November 2023
10 November 2023
Zepbound (tirzepatide) has been approved by the FDA approval and is expected to be launched in the US by the end of 2023.
Eccogene will receive $185m upfront and up to $1.82bn in payments from AstraZeneca for the small molecule GLP-1 agonist.
Recursion is entitled to receive development and commercial milestone payments of $1.5bn.
The company has prioritised the development of ADI-270 in renal cell carcinoma while pausing the preclinical development of ADI-925.
New sustainable child-resistant packaging technologies need to be prioritised to avoid drug recalls.
The approval is based on findings from a Phase III trial and continuation study of Adzynma in cTTP patients.
Patients in the US who were previously treated for metastatic colorectal cancer are now cleared to use Takeda’s chemotherapy-free drug.
The development is based on data from the Phase III QuANTUM-First clinical trial of the Vanflyta combination regimen.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.
Give your business an edge with our leading industry insights.
